It is alleged in the complaint that throughout the Class Period, Innate made misleading and/or false statements and/or failed to disclose that: (1) Innate presented the results of their various Phase 2 trials as having been within expectations; (2) Innate continued to reassure investors of their eligibility, upon first dosing of Phase 3 trials, for the $100 million payment; (3) Innate failed to timely disclose their renegotiations with AstraZeneca aimed at splitting the $100 million payment into two $50 million payments, which would be partially contingent on performance during the Phase 3 trials; and (4) as a result, Innate’s statements about its operations, business, and prospects, were materially misleading and false and/or lacked a reasonable basis at all relevant times.
Innate Pharma, S.A.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to email@example.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at firstname.lastname@example.org.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
1800 Century Park East, Suite 600
Los Angeles, CA 90067